Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

Novel therapeutic approach in a multiplicity of neurodegenerative and autoinflammatory pathologies

Country of Origin: Italy
Reference Number: TOIT20190416001
Publication Date: 19 April 2019


An Italian research group has developed new therapeutic approaches to neurodegenerative and autoinflammatory pathologies. The research group is interested in finding partners for developing the research targeting neurological diseases. Partners may be pharmaceutical companies, startup or other research groups interested in research collaborations, in technical or research cooperation agreements or in financial agreements for future developments of a product.


Recent findings have highlighted the important role played by the disregulated activation of the innate immune system in the onset and progression of several neurological and autoinflammatory diseases. Small organic molecules able to modulate the activation of the immune system have, therefore, a great potential in the identification of a therapeutic approach for a multiplicity of neurodegenerative and autoinflammatory pathologies. The inhibition of the caspase-1 enzyme may allow to modulate the release of proinflammatory cytokines deriving from the activation of the inflammasome, blocking the inflammatory process. To date, there are no caspase-1 inhibitors that can be used in the clinic. In fact, although numerous caspase-1 inhibitors have been synthesized, no inhibitor has passed the clinical trial, probably because of the covalent mechanism of action and the consequent unwanted off-target interactions. 
The research group, in collaboration with a foreign University, is interested in finding possible partners with whome to complete the pre-clinical study and further develop the technology through technical or research cooperation agreements or financial agreements.

Advantages and Innovations

The research result and patent related, claims a new class of molecules able to inhibit caspase-1 to modulate innate immune system and in inflammatory processes. The new molecules discovered present innovative characteristics, with respect to the molecules currently known, because of their non-covalent mechanism of action.

Stage Of Development

Under development/lab tested

Requested partner

Pharmaceutical companies interested in further developing the product.

Kooperationsanfrage stellen